Literature DB >> 28243631

Identifying microRNA panels specifically associated with hepatocellular carcinoma and its different etiologies.

Jing Shen1, Abby B Siegel2, Helen Remotti3, Qiao Wang1, Regina M Santella1.   

Abstract

AIM: Deregulation of microRNAs (miRNAs) expression has been identified in hepatocellular carcinoma (HCC), but few results are consistent. The objective of this study is to investigate "HCC tumor type specific" and "tumor common" miRNA panels.
METHODS: The authors integrate and analyze clinical, etiologic and miRNA profiles data from 9 types of solid tumors in The Cancer Genome Atlas (TCGA) and HCC data from Columbia University Medical Center (CUMC).
RESULTS: Levels of 33 miRNAs were significant different between HCC tumor and paired non-tumor tissues (over 2-fold changes) after Bonferroni correction for multiple comparisons, and most (28 miRNAs) were down-regulated in HCC tumors. Using this panel, the authors well classified HCC tumor tissues with 4 misclassifications among 48 paired tissues. Validating this panel in an additional 302 HCC tumor tissues, the authors almost perfectly distinguished tumor from non-tumor tissues with only two misclassifications (99% of HCC tissues correctly classified). Evaluating miRNA profiles in 32 independent HCC paired tissues from CUMC, the authors observed 40 miRNAs significantly deregulated in HCC with over 2-fold changes; 14 overlapped with those identified in TCGA. Subgroup analyses by HCC etiology found that 4 upregulated and 8 downregulated miRNAs were significantly associated with alcohol-related HCC. There were 7 and 4 miRNAs significantly associated with hepatitis B virus- and hepatitis C virus-related HCC, respectively. Data for the first time revealed that miR-24-1, miR-130a and miR-505 were significantly down-regulated only in HCC tumors; miR-142 and miR-455 were significantly down-regulated in HCC, but up-regulated in 5 other solid tumors; suggesting their HCC "tumor type specific" characteristics. A panel of 8 miRNAs was significant in at least 5 tumor types, including HCC, and was identified as "tumor common" marker.
CONCLUSION: The authors concluded that aberrant miRNA panels have HCC "tumor type specificity" and may be affected by etiologic factors.

Entities:  

Keywords:  MicroRNA; The Cancer Genome Atlas; etiologies; hepatocellular carcinoma

Year:  2016        PMID: 28243631      PMCID: PMC5325160          DOI: 10.20517/2394-5079.2015.66

Source DB:  PubMed          Journal:  Hepatoma Res        ISSN: 2394-5079


  62 in total

1.  Investigation of the value of miR-21 in the diagnosis of early stage HCC and its prognosis: a meta-analysis.

Authors:  S R Yan; Z J Liu; S Yu; Y X Bao
Journal:  Genet Mol Res       Date:  2015-09-28

Review 2.  Current State of Circulating MicroRNAs as Cancer Biomarkers.

Authors:  Yuqing He; Juanjuan Lin; Danli Kong; Mingyuan Huang; Chengkai Xu; Taek-Kyun Kim; Alton Etheridge; Yanhong Luo; Yuanlin Ding; Kai Wang
Journal:  Clin Chem       Date:  2015-08-03       Impact factor: 8.327

3.  Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkers.

Authors:  Li-Ya Chiu; Priya S Kishnani; Tzu-Po Chuang; Cheng-Yang Tang; Cheng-Yuan Liu; Deeksha Bali; Dwight Koeberl; Stephanie Austin; Keri Boyette; David A Weinstein; Elaine Murphy; Adam Yao; Yuan-Tsong Chen; Ling-Hui Li
Journal:  J Gastroenterol       Date:  2013-10-16       Impact factor: 7.527

4.  Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma.

Authors:  Fan-Long Meng; Wei Wang; Wei-Dong Jia
Journal:  Med Oncol       Date:  2014-08-17       Impact factor: 3.064

5.  Quantification of microRNA expression with next-generation sequencing.

Authors:  Seda Eminaga; Danos C Christodoulou; Francois Vigneault; George M Church; J G Seidman
Journal:  Curr Protoc Mol Biol       Date:  2013-07

Review 6.  MiR-139-5p: promising biomarker for cancer.

Authors:  He-da Zhang; Lin-hong Jiang; Da-wei Sun; Jian Li; Jin-hai Tang
Journal:  Tumour Biol       Date:  2015-02-19

7.  Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A.

Authors:  Joydip Bhanja Chowdhury; Shubham Shrivastava; Robert Steele; Adrian M Di Bisceglie; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

8.  Upregulation of miR-34a-5p antagonizes AFB1-induced genotoxicity in F344 rat liver.

Authors:  Caixia Liu; Haohui Yu; Yan Zhang; Daochuan Li; Xiumei Xing; Liping Chen; Xiaowen Zeng; Dandan Xu; Qiming Fan; Yongmei Xiao; Wen Chen; Qing Wang
Journal:  Toxicon       Date:  2015-09-16       Impact factor: 3.033

Review 9.  Aflatoxins as risk factors for hepatocellular carcinoma in humans.

Authors:  G N Wogan
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

10.  Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment.

Authors:  Medhat S El-Halawany; Heba M Ismail; Ahmed A Zeeneldin; Ammar Elfiky; Marwa Tantawy; Mohamed H Kobaisi; Ikram Hamed; Abdel Hady A Abdel Wahab
Journal:  Biomed Res Int       Date:  2015-02-25       Impact factor: 3.411

View more
  7 in total

Review 1.  Systems Challenges of Hepatic Carcinomas: A Review.

Authors:  Dhatri Madduru; Johny Ijaq; Sujata Dhar; Saumyadip Sarkar; Naresh Poondla; Partha S Das; Silvia Vasquez; Prashanth Suravajhala
Journal:  J Clin Exp Hepatol       Date:  2018-05-17

2.  The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells.

Authors:  Zhangding Wang; Qiang Wang; Guifang Xu; Na Meng; Xinli Huang; Zerun Jiang; Chen Chen; Yan Zhang; Junjie Chen; Aiping Li; Nan Li; Xiaoping Zou; Jianwei Zhou; Qingqing Ding; Shouyu Wang
Journal:  RNA Biol       Date:  2020-01-07       Impact factor: 4.652

3.  MicroRNA-505-5p functions as a tumor suppressor by targeting cyclin-dependent kinase 5 in cervical cancer.

Authors:  Elena Kapora; Shujun Feng; Wei Liu; Indira Sakhautdinova; Bo Gao; Wenhua Tan
Journal:  Biosci Rep       Date:  2019-07-25       Impact factor: 3.840

4.  Long noncoding RNA DLX6-AS1 promotes liver cancer by increasing the expression of WEE1 via targeting miR-424-5p.

Authors:  Dan Li; Xianbin Tang; Man Li; Yi Zheng
Journal:  J Cell Biochem       Date:  2019-02-25       Impact factor: 4.429

5.  Prognostic value and prospective molecular mechanism of miR-100-5p in hepatocellular carcinoma: A comprehensive study based on 1,258 samples.

Authors:  Qing-Lin He; Shan-Yu Qin; Lin Tao; Hong-Jian Ning; Hai-Xing Jiang
Journal:  Oncol Lett       Date:  2019-10-04       Impact factor: 2.967

6.  HNF-4α inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway.

Authors:  Guang Yang; Min Zhang; Yawei Zhao; Yue Pan; Mujie Kan; Jing Li; Kan He; Xuewen Zhang
Journal:  PLoS One       Date:  2020-03-25       Impact factor: 3.240

7.  Dexmedetomidine promotes apoptosis and suppresses proliferation of hepatocellular carcinoma cells via microRNA-130a/EGR1 axis.

Authors:  Lei Zhou; Juanni Li; Xing Liu; Yongzhong Tang; Tunliang Li; Huiyin Deng; Jia Chen; Xinlin Yin; Kuan Hu; Wen Ouyang
Journal:  Cell Death Discov       Date:  2022-01-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.